Clinical Trials
17 trialsNCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02580994 2023-12-11
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02934503 2021-11-16
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
Phase 2 Terminated
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT01237678 2018-01-18
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
ImmunoGen, Inc.
Phase 1/2 Terminated
NCT00807755 2018-01-09
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
Phase 1 Terminated
NCT00003657 2017-01-20
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01160731 2014-12-31
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Cancer Trials Ireland
Phase 1 Withdrawn
NCT00433498 2014-12-03
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
University College, London
Phase 3 Completed
NCT00240097 2014-11-27
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
University of Alabama at Birmingham
Phase 2 Completed
NCT00011921 2013-09-17
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00927875 2013-06-03
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00621361 2012-12-17
Phase I Safety and Tolerability Study of Cediranib (RECENTINâ„¢, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
AstraZeneca
Phase 1 Completed
NCT01416961 2012-08-22
Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT01563601 2012-08-15
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Withdrawn
NCT00191139 2010-02-17
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed